Premium
Technetium‐99 m labelling of DD‐3B6/22 antifibrin monoclonal antibody fragment Fab′ for thrombus imaging
Author(s) -
LEE FT.,
BONIFACE G. R.,
LAMBRECHT R. M.,
RYLATT D. B.,
BUNDESEN P. G.
Publication year - 1993
Publication title -
immunology and cell biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.999
H-Index - 104
eISSN - 1440-1711
pISSN - 0818-9641
DOI - 10.1038/icb.1993.12
Subject(s) - monoclonal antibody , conjugate , chemistry , antibody , in vivo , labelling , technetium , technetium 99m , biodistribution , microbiology and biotechnology , monoclonal , immunoglobulin fab fragments , immunoscintigraphy , in vitro , scintigraphy , biochemistry , radioimmunotherapy , nuclear medicine , immunology , biology , medicine , nuclear chemistry , mathematical analysis , mathematics , complementarity determining region
Summary The antifibrin DD‐3B6/22 monoclonal antibody Fab′ fragment, a murine immunoglobulin, IgG3, has been labelled with technetium‐99 m ( 99m Tc) via a transchelation reaction, to specific activity in excess of 30 mCi/mg protein. The radio labelling of Fab′ was dependent on time, temperature, pH, antibody concentrations and nature of intermediary transchelation complex used. The resultant radio conjugate was stable in vitro and in vivo. Blood clearance of 99m Tc‐Fab′ in rat followed two compartment kinetics with the half time of the fast phase being 0.5 h. The main route of excretion was via the kidneys with little uptake indicated by other tissues. The results suggest that the inherent specificity of the antibody, small molecular size, rapid plasma clearance, high specific radioactivity, together with the physical properties of the 99m Tc label, combine to make this labeled monoclonal antibody (MoAb), potentially suitable as a radiopharmaceutical for the scintigraphic detection of thrombi in humans.